lenalidomide has been researched along with decitabine in 47 studies
| Studies (lenalidomide) | Trials (lenalidomide) | Recent Studies (post-2010) (lenalidomide) | Studies (decitabine) | Trials (decitabine) | Recent Studies (post-2010) (decitabine) |
|---|---|---|---|---|---|
| 3,532 | 725 | 2,850 | 3,804 | 205 | 2,177 |
| Protein | Taxonomy | lenalidomide (IC50) | decitabine (IC50) |
|---|---|---|---|
| DNA (cytosine-5)-methyltransferase 1 | Homo sapiens (human) | 0.03 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 21 (44.68) | 29.6817 |
| 2010's | 26 (55.32) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| List, AF | 1 |
| Steensma, DP; Tefferi, A | 1 |
| Schiffer, CA | 1 |
| Sloand, EM | 1 |
| Garcia-Manero, G; Jagasia, M; Yang, AS | 1 |
| Mitani, K | 1 |
| Miyazawa, K | 1 |
| Nomdedeu, B | 1 |
| Stone, RM | 2 |
| Estey, E; Scott, BL | 1 |
| Gore, SD | 1 |
| Basile, FG | 1 |
| Garcia-Manero, G; Lyons, RM; Sekeres, M; Stone, R | 1 |
| Fenaux, P; Itzykson, R | 1 |
| Galili, N; Raza, A | 2 |
| Gotlib, J; Greenberg, PL | 1 |
| Ishikawa, T | 2 |
| Sekeres, MA | 1 |
| Lachs, MS; Ritchie, EK | 1 |
| Koppel, A; Schiller, G | 1 |
| Fenaux, P; Garcia-Manero, G | 1 |
| Baer, MR; Gojo, I | 1 |
| Garcia-Manero, G | 2 |
| Tohyama, K | 1 |
| Cluzeau, T; Fenaux, P | 1 |
| Brower, V | 1 |
| Matsumura, I; Morita, Y; Tanaka, H | 1 |
| Schleiffenbaum, BE | 1 |
| Duong, VH; Komrokji, RS; List, AF | 1 |
| Klimek, V | 1 |
| Mukherjee, S; Ornstein, MC; Sekeres, MA | 1 |
| Ali, A; Itzykson, R; Loiseau, C | 1 |
| DeZern, AE | 1 |
| Balleari, E; Bernal, T; Beyne-Rauzy, O; Bordessoule, D; Calabuig, M; Cametti, G; Campelo, MD; Cheze, S; Cony-Makhoul, P; Dreyfus, F; Fenaux, P; Fensterl, J; Ferrero, D; Gaidano, G; Germing, U; Gioia, D; Götze, K; Guerci-Bresler, A; Hamel, JF; Kaivers, J; Kelaidi, C; Komrokji, R; Kotsianidis, I; Müller-Thomas, C; Pane, F; Park, S; Ramos, F; Roboz, GJ; Rose, C; Sanna, A; Santini, V; Sanz, GF; Sapena, R; Sekeres, MA; Stamatoullas, A; Steensma, DP; Thépot, S; Toma, A; Vey, N; Wattel, E | 1 |
| Binder, G; Broder, MS; Chang, E; Cogle, CR; McGuire, M; Papoyan, E; Reddy, SR | 1 |
| Dodillet, H; Kreuzer, KA; Monsef, I; Skoetz, N | 1 |
| Kiselev, P; Ma, X; Scott, BL; Steensma, DP; Sugrue, MM; Swern, AS | 1 |
| Ali, A; Montoro, J; Raza, A; Yerlikaya, A | 1 |
| Estey, EH; Percival, MM | 1 |
| Gattermann, N; Germing, U; Kaivers, J; Kobbe, G; Kündgen, A; Schroeder, T | 1 |
| Steensma, DP | 1 |
28 review(s) available for lenalidomide and decitabine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Risk-based management of myelodysplastic syndrome.
Topics: Anemia, Sideroblastic; Antilymphocyte Serum; Azacitidine; Benzoates; Decitabine; Deferasirox; DNA Modification Methylases; Enzyme Inhibitors; Erythropoietin; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Histone Deacetylase Inhibitors; Humans; Immunosuppressive Agents; Interleukin-11; Iron Chelating Agents; Lenalidomide; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes; Prognosis; Risk; Stem Cell Transplantation; Thalidomide; Triazoles | 2007 |
Myelodysplasia: the good, the fair and the ugly.
Topics: Antilymphocyte Serum; Antineoplastic Agents; Azacitidine; Bone Marrow Transplantation; Clinical Trials as Topic; Decitabine; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppression Therapy; Lenalidomide; Myelodysplastic Syndromes; Thalidomide | 2007 |
Evaluating new treatment options for MDS.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Clinical Trials as Topic; Decitabine; Epigenesis, Genetic; Humans; Immunologic Factors; Lenalidomide; Myelodysplastic Syndromes; Survival Analysis; Thalidomide | 2007 |
[Myelodysplastic syndrome].
Topics: alpha Catenin; Antineoplastic Agents; Azacitidine; Cholecalciferol; Cyclosporine; Decitabine; Drug Therapy, Combination; Humans; Immunosuppressive Agents; Lenalidomide; Myelodysplastic Syndromes; Prognosis; Thalidomide; Vitamin K 2; World Health Organization | 2008 |
[Pathogenesis of and therapeutic progress for myelodysplastic syndromes].
Topics: Azacitidine; Clinical Trials as Topic; Decitabine; Deoxycytidine; DNA Methylation; Drug Design; Gene Targeting; Humans; Iron Chelating Agents; Lenalidomide; Myelodysplastic Syndromes; Thalidomide; Tumor Necrosis Factor-alpha | 2008 |
Are new agents really making a difference in MDS?
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Decitabine; Humans; Lenalidomide; Myelodysplastic Syndromes; Thalidomide; Treatment Outcome | 2008 |
Management of myelodysplastic syndromes: 2008 update.
Topics: Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Clinical Trials as Topic; Decitabine; Disease-Free Survival; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Hematinics; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Iron Chelating Agents; Lenalidomide; Myelodysplastic Syndromes; Survival Analysis; Thalidomide; Treatment Outcome | 2008 |
How I treat patients with myelodysplastic syndromes.
Topics: Acute Disease; Aged; Azacitidine; Chelation Therapy; Chromosome Deletion; Chromosomes, Human, Pair 5; Clinical Trials as Topic; Decitabine; Disease Progression; DNA Methylation; Erythropoietin; Hematopoietic Cell Growth Factors; Hematopoietic Stem Cell Transplantation; Humans; Iron Chelating Agents; Lenalidomide; Leukemia, Myeloid; Myelodysplastic Syndromes; Severity of Illness Index; Thalidomide; Transplantation, Homologous | 2009 |
Optimal sequencing of treatments for patients with myelodysplastic syndromes.
Topics: Azacitidine; Decitabine; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Myelodysplastic Syndromes; Thalidomide; Transplantation, Homologous | 2009 |
Novel biospecific agents for the treatment of myelodysplastic syndromes.
Topics: Arsenic Trioxide; Arsenicals; Azacitidine; Decitabine; Etanercept; Farnesyltranstransferase; Humans; Immunoglobulin G; Lenalidomide; Myelodysplastic Syndromes; Oxides; Receptors, Tumor Necrosis Factor; Thalidomide | 2003 |
[Novel therapeutic agents for myelodysplastic syndrome].
Topics: Antineoplastic Agents; Azacitidine; Clinical Trials as Topic; Decitabine; Drug Discovery; Drug Therapy, Combination; Erythropoietin; Humans; Lenalidomide; Myelodysplastic Syndromes; Randomized Controlled Trials as Topic; Remission Induction; Thalidomide | 2009 |
Treatment of MDS: something old, something new, something borrowed...
Topics: Azacitidine; Benzoates; Blood Transfusion; Bone Marrow Diseases; Chromosome Deletion; Chromosomes, Human, Pair 5; Clinical Trials as Topic; Combined Modality Therapy; Decitabine; DNA-Cytosine Methylases; Glutathione; Hematinics; Humans; Hydrazines; Immunologic Factors; Lenalidomide; Myelodysplastic Syndromes; Pyrazoles; Randomized Controlled Trials as Topic; Receptors, Fc; Recombinant Fusion Proteins; Risk; Thalidomide; Thrombopoietin | 2009 |
Pharmacotherapy of myelodysplastic syndromes.
Topics: Azacitidine; Decitabine; DNA Methylation; Drug Approval; Erythropoietin; Humans; Iron Chelating Agents; Lenalidomide; Myelodysplastic Syndromes; Recombinant Proteins; Thalidomide; United States; United States Food and Drug Administration | 2010 |
Hypomethylating agents and other novel strategies in myelodysplastic syndromes.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Decitabine; DNA Methylation; Epoetin Alfa; Erythropoietin; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Lenalidomide; Myelodysplastic Syndromes; Prognosis; Recombinant Proteins; Thalidomide; Transplantation, Homologous | 2011 |
Treatment of higher-risk myelodysplastic syndrome.
Topics: Algorithms; Antineoplastic Agents; Azacitidine; Combined Modality Therapy; Decitabine; DNA Methylation; Drug Therapy, Combination; Enzyme Inhibitors; Histone Deacetylase Inhibitors; Humans; Lenalidomide; Myelodysplastic Syndromes; Patient Selection; Stem Cell Transplantation; Thalidomide | 2011 |
[Novel therapeutics for myelodysplastic syndromes].
Topics: Azacitidine; Decitabine; DNA Methylation; Humans; Lenalidomide; Myelodysplastic Syndromes; Thalidomide | 2011 |
[New tools and treatments in myelodysplastic syndromes].
Topics: Antimetabolites, Antineoplastic; Azacitidine; Blood Transfusion; Cytogenetics; Decitabine; Flow Cytometry; Gene Expression Profiling; Humans; Immunologic Factors; Lenalidomide; Mutation; Myelodysplastic Syndromes; Prognosis; Thalidomide | 2013 |
Novel therapeutic strategies using hypomethylating agents in the treatment of myelodysplastic syndrome.
Topics: Azacitidine; Benzamides; Decitabine; DNA Methylation; Humans; Imatinib Mesylate; Lenalidomide; Molecular Targeted Therapy; Myelodysplastic Syndromes; Piperazines; Pyrimidines; Thalidomide | 2014 |
Update on the pharmacotherapy for myelodysplastic syndromes.
Topics: Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Azacitidine; Clinical Trials as Topic; Decitabine; DNA Modification Methylases; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Lenalidomide; Myelodysplastic Syndromes; Prognosis; Remission Induction; Risk Assessment; Thalidomide | 2014 |
More is better: combination therapies for myelodysplastic syndromes.
Topics: Antineoplastic Agents; Azacitidine; Benzamides; Clinical Trials as Topic; Decitabine; Disease Progression; Drug Therapy, Combination; Gene Expression; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hydroxamic Acids; Lenalidomide; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Pyrimidines; Thalidomide; Valproic Acid; Vorinostat | 2015 |
New therapeutic approaches in myelodysplastic syndromes: Hypomethylating agents and lenalidomide.
Topics: Angiogenesis Inhibitors; Animals; Antimetabolites, Antineoplastic; Azacitidine; Clinical Trials, Phase III as Topic; Decitabine; Humans; Lenalidomide; Myelodysplastic Syndromes; Randomized Controlled Trials as Topic; Thalidomide; Translational Research, Biomedical | 2015 |
Myelodysplastic syndromes: 2015 Update on diagnosis, risk-stratification and management.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Bone Marrow; Decitabine; Disease Management; Disease Progression; Hematopoietic Stem Cell Transplantation; Humans; Intercellular Signaling Peptides and Proteins; Karyotype; Lenalidomide; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Research Design; Thalidomide; Transplantation, Homologous | 2015 |
Thrombopoietin mimetics for patients with myelodysplastic syndromes.
Topics: Adult; Azacitidine; Benzoates; Blood Transfusion; Decitabine; Female; Hemorrhage; Humans; Hydrazines; Lenalidomide; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Pyrazoles; Quality of Life; Randomized Controlled Trials as Topic; Receptors, Fc; Recombinant Fusion Proteins; Thalidomide; Thrombocytopenia; Thrombopoietin | 2017 |
Improving Treatment for Myelodysplastic Syndromes Patients.
Topics: Aging; Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Enzyme Inhibitors; Humans; Lenalidomide; Myelodysplastic Syndromes; Stem Cell Transplantation; Transplantation, Homologous | 2018 |
Current treatment strategies for measurable residual disease in patients with acute myeloid leukemia.
Topics: Aminopyridines; Aniline Compounds; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Immunological; Azacitidine; Cytogenetic Analysis; Decitabine; Enzyme Inhibitors; Flow Cytometry; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Immunologic Factors; In Situ Hybridization, Fluorescence; Lenalidomide; Leukemia, Myeloid, Acute; Molecular Diagnostic Techniques; Neoplasm, Residual; Nivolumab; para-Aminobenzoates; Protein Kinase Inhibitors; Pyrazines; Pyrrolidines; Recombinant Fusion Proteins; Remission Induction; Transplantation, Homologous; Triazines; Triazoles | 2019 |
Novel therapies in low- and high-risk myelodysplastic syndrome.
Topics: Activin Receptors, Type II; Anemia; Antineoplastic Agents; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Decitabine; Erythrocyte Transfusion; Hematinics; Humans; Immunoglobulin Fc Fragments; Iron Chelating Agents; Lenalidomide; Myelodysplastic Syndromes; Oligonucleotides; Prognosis; Recombinant Fusion Proteins; Risk Assessment; Stem Cell Transplantation; Sulfonamides; Thalidomide; Thrombopoietin; Transplantation, Homologous | 2019 |
Does early diagnosis and treatment of myelodysplastic syndromes make a difference?
Topics: Allografts; Azacitidine; Decitabine; Early Diagnosis; Hematinics; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Myelodysplastic Syndromes; Risk Factors | 2019 |
19 other study(ies) available for lenalidomide and decitabine
| Article | Year |
|---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
New agents in the treatment of MDS.
Topics: Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Azacitidine; Clinical Trials, Phase III as Topic; Decitabine; Enzyme Inhibitors; Humans; Indoles; Lenalidomide; Myelodysplastic Syndromes; Predictive Value of Tests; Thalidomide; Treatment Outcome | 2005 |
Myelodysplastic syndromes: introduction.
Topics: Azacitidine; Decitabine; Hematopoietic Stem Cell Transplantation; Humans; Intercellular Signaling Peptides and Proteins; Lenalidomide; Myelodysplastic Syndromes; Thalidomide | 2008 |
[Myelodysplastic syndromes: therapeutic advances and promising future].
Topics: Antineoplastic Agents; Azacitidine; Decitabine; Forecasting; Humans; Lenalidomide; Myelodysplastic Syndromes; Thalidomide | 2008 |
New agents for the treatment of AML recent study findings.
Topics: Adenine Nucleotides; Antineoplastic Agents; Arabinonucleosides; Azacitidine; Carbazoles; Clofarabine; Decitabine; Enzyme Inhibitors; Furans; Humans; Hydrazines; Immunotherapy; Lenalidomide; Leukemia, Myeloid, Acute; Quinolones; Staurosporine; Sulfonamides; Thalidomide | 2008 |
Durable clinical and cytogenetic remission in an elderly patient with relapsed acute myeloid leukemia treated with low-dose lenalidomide.
Topics: Acute Disease; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Azacitidine; Blood Transfusion; Chromosome Deletion; Chromosomes, Human, Pair 5; Decitabine; Humans; Lenalidomide; Leukemia, Myeloid; Male; Neoplasm Recurrence, Local; Remission Induction; Thalidomide | 2009 |
Recent advances in low- and intermediate-1-risk myelodysplastic syndrome: developing a consensus for optimal therapy.
Topics: Age Factors; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Blood Transfusion; Clinical Trials as Topic; Consensus; Decitabine; Humans; Lenalidomide; Middle Aged; Myelodysplastic Syndromes; Prognosis; Risk Factors; Thalidomide | 2008 |
Clinical implications of gene expression profiling in myelodysplastic syndromes: recognition of ribosomal and translational gene dysregulation and development of predictive assays.
Topics: Antigens, CD34; Azacitidine; Cell Proliferation; Decitabine; Drug Resistance, Neoplasm; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lenalidomide; Myelodysplastic Syndromes; Protein Biosynthesis; Ribosomes; Thalidomide | 2009 |
Management of myelodysplastic syndromes in the geriatric patient.
Topics: Aged; Anemia; Antineoplastic Agents; Azacitidine; Decitabine; Erythrocyte Transfusion; Erythropoietin; Humans; Iron Chelating Agents; Lenalidomide; Myelodysplastic Syndromes; Neutropenia; Thalidomide; Thrombocytopenia | 2009 |
Myelodysplastic syndrome: An update on diagnosis and therapy.
Topics: Antineoplastic Agents; Azacitidine; Cytogenetic Analysis; Decitabine; Flow Cytometry; Histone Deacetylase Inhibitors; Humans; Immunohistochemistry; Lenalidomide; Myelodysplastic Syndromes; Prognosis; Severity of Illness Index; Thalidomide | 2009 |
Novel agents for the treatment of acute myeloid leukemia in the older patient.
Topics: Adenine Nucleotides; Age Factors; Aged; Antineoplastic Agents; Arabinonucleosides; Azacitidine; Clofarabine; Cytosine; Decitabine; Disease-Free Survival; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Middle Aged; Prognosis; Quinolones; Thalidomide | 2011 |
Improving the outlook for myelodysplastic syndrome.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Biomarkers, Tumor; Decitabine; Disease Progression; DNA Methylation; Enzyme Inhibitors; Epigenesis, Genetic; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Methyltransferases; Molecular Targeted Therapy; Myelodysplastic Syndromes; Phosphoproteins; Point Mutation; Prognosis; Ribonucleoprotein, U2 Small Nuclear; Risk Assessment; RNA Splicing; RNA Splicing Factors; Spliceosomes; Thalidomide | 2012 |
[Molecular target therapy for myelodysplastic syndrome].
Topics: Antimetabolites, Antineoplastic; Azacitidine; Cytokines; Decitabine; Epigenesis, Genetic; Histone Deacetylase Inhibitors; Humans; Lenalidomide; Molecular Targeted Therapy; Myelodysplastic Syndromes; Thalidomide; Tumor Necrosis Factor-alpha; Vascular Endothelial Growth Factor A | 2012 |
[CME myelodysplasia - a frequent hematologic neoplasia in the elderly].
Topics: Aged, 80 and over; Anemia, Aplastic; Azacitidine; Bone Marrow; Bone Marrow Examination; Cell Proliferation; Cell Transformation, Neoplastic; Decitabine; Diagnosis, Differential; Disease Progression; Hematopoiesis; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Prognosis; Thalidomide | 2014 |
Myelodysplastic syndromes (MDS).
Topics: Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Humans; Immunologic Factors; Karyotyping; Lenalidomide; Myelodysplastic Syndromes; Thalidomide | 2015 |
Nine years without a new FDA-approved therapy for MDS: how can we break through the impasse?
Topics: Algorithms; Azacitidine; Clinical Trials as Topic; Decitabine; Drug Approval; Drug Industry; Humans; Karyotyping; Lenalidomide; Methylation; Mutation; Myelodysplastic Syndromes; Prognosis; Risk Assessment; Thalidomide; United States; United States Food and Drug Administration | 2015 |
Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents.
Topics: Aged; Aged, 80 and over; Anemia; Antilymphocyte Serum; Antineoplastic Agents; Arsenic; Azacitidine; Chromosome Deletion; Chromosomes, Human, Pair 5; Cyclosporine; Cytarabine; Decitabine; Disease Progression; Enzyme Inhibitors; Erythrocyte Transfusion; Female; Hematinics; Humans; Hydroxyurea; Immunologic Factors; Lenalidomide; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Recurrence; Retreatment; Retrospective Studies; Risk Factors; Survival Rate; Thalidomide; Treatment Failure; Tretinoin; Valproic Acid | 2017 |
Early treatment initiation in lower-risk myelodysplastic syndromes produces an earlier and higher rate of transfusion independence.
Topics: Aged; Aged, 80 and over; Azacitidine; Blood Transfusion; Decitabine; Female; Hematinics; Humans; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Secondary Prevention; Thalidomide; Time Factors | 2017 |
Selection of patients with myelodysplastic syndromes from a large electronic medical records database and a study of the use of disease-modifying therapy in the United States.
Topics: Aged; Aged, 80 and over; Anemia; Azacitidine; Databases, Factual; Decitabine; Electronic Health Records; Enzyme Inhibitors; Female; Hematinics; Humans; Immunologic Factors; Iron Chelating Agents; Lenalidomide; Male; Middle Aged; Multivariate Analysis; Myelodysplastic Syndromes; Proportional Hazards Models; Recurrence; Retrospective Studies; Thalidomide; Treatment Outcome; United States | 2018 |